BRASTER S.A., Polish innovative company using liquid crystal contact thermography technology for breast oncology, registered its another U.S. patent. The specific protection of the intellectual property and know-how covers both the unique liquid crystal emulsion and the manufacturing process invented and elaborated by BRASTER S.A.’s researchers. This means the technology for the manufacture of the crucial liquid crystal matrices applied in the TESTER used for early breast pathology detection will be protected on the U.S. market and the Company has the exclusive right to manufacture the matrices.

The TESTER, invented by Polish researchers, is the world’s first device using liquid crystal thermographic matrices for diagnosing breast cancer. As acknowledged by the ThermaCRAC Trial completed in 2013, the TESTER is an efficient diagnostic tool complementary to mammography and ultrasonography, which significantly improves the odds for detecting cancer at a very early development stage.

The device consists of three matrices covered with film coated with a mix of liquid crystals that enables thermal imaging. The TESTER is user-friendly and non-invasive, which means painless and completely safe to the patient. It neither emits nor uses any harmful radiation and is biologically neutral to the skin. The TESTER can be an important accessory in screening a broad range of patients for breast cancer, irrespective of age, tissue structure or temperature.

"This is another breakthrough step taking our unique technology and its product, the TESTER, closer to the market launch. What is also important is that the U.S. Patent Office is a top-ranking institution in terms of reputation and its patents are crucial for businesses worldwide. BRASTER S.A. is a member of the club." - said Krzysztof Pawelczyk, BRASTER S.A.’s President.

"The patent protection secures our inventions and BRASTER has the exclusive right to exploit its technology commercially. This is certainly excellent news for both the authors of the technology and all our shareholders since one of the greatest global markets is opening to us and our TESTER. Meeting all the strict requirements of the U.S. Patent Office has confirmed we have been consistently pursuing our goals related to the global market launch of the TESTER.” - said Krzysztof Pawelczyk, BRASTER S.A.'s President.

See also

Braster device – proven breakthrough in breast cancer diagnostics

Read More
Braster device – proven breakthrough in breast cancer diagnostics
1 day 5 days 1 month Period from: to: Volume Share price pl

Raty PayU to możliwość zapłacenia za zakupy w ratach (od 3 do nawet 36)

We use cookies to improve the quality of our service. Using our website without changing the cookie settings in your browser means that you agree to have them saved or used. You can find more information in the Privacy and Cookie Policy